-
公开(公告)号:US20250011425A1
公开(公告)日:2025-01-09
申请号:US18754353
申请日:2024-06-26
Abstract: The invention provides compositions and methods for generating improved T cells having increased Ezh2 activity and methods of use thereof in the treatment of cancer and chronic infection.
-
公开(公告)号:US20200270573A1
公开(公告)日:2020-08-27
申请号:US16761599
申请日:2018-11-07
Abstract: The invention provides compositions and methods for generating improved T cells having increased Ezh2 activity and methods of use thereof in the treatment of cancer and chronic infection.
-
公开(公告)号:US12024715B2
公开(公告)日:2024-07-02
申请号:US16761599
申请日:2018-11-07
CPC classification number: C12N5/0636 , A61K35/17 , A61P35/00 , C07K16/2803 , C12N9/1007 , C12N15/85 , C12Y201/01043 , C07K2317/24 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C12N2510/00
Abstract: The invention provides compositions and methods for generating improved T cells having increased Ezh2 activity and methods of use thereof in the treatment of cancer and chronic infection.
-
公开(公告)号:US20190134169A1
公开(公告)日:2019-05-09
申请号:US16095986
申请日:2017-04-26
Inventor: Yi Zhang , Lijun Meng , Shan He
Abstract: Methods are provided for generating DLL4-expressing immune cells. The invention also includes cellular compositions of dendritic and T cells produced by these methods. The immune cells of the invention can be used widely as components in many diagnostic and therapeutic systems, including improved vaccines to reduce the risk of graft versus host disease.
-
-
-